Lenovo Outlines Company Transformation Strategy - From Devices To Solutions Company
14.4.2021 18:00:00 EEST | Business Wire | Press release
Today, during its annual global employee kickoff event broadcast to 63,000 employees, Lenovo unveiled its plans to drive transformation from a global devices company to a technology leader in global devices + solutions, services, and software. Lenovo CEO Yang Yuanqing and other executive leaders outlined the company’s strategy, structure, and goals that will fuel Lenovo’s next decade of growth and position it as one of the world’s most trusted and iconic technology leaders, delivering smarter technology for all.
“Last year at this time, none of us knew how things would turn out for Lenovo,” said Lenovo CEO Yuanqing Yang. “But we did know this: we would support each other in an unpredictable journey ahead; we would fight for the best possible outcome in an uncertain world; and we would use our technology to connect and heal a wounded society.”
During the past year the COVID pandemic drove many businesses and consumers around the world to adopt and use technology innovations in new ways, from remote learning to treating patients to pivoting their business models. They counted on Lenovo’s unique ability to provide the devices and solutions they needed to survive and thrive in this challenging environment. Lenovo’s committed, diverse global workforce ensured the company met the global need for technology solutions being the first to resume manufacturing after facilities closed early on in the pandemic, building a new factory in 47 days, and launching an impactful charitable donation effort.
Unparalleled Growth for Company’s Fourth Transformation
Lenovo’s operational and workforce resilience has led to significant growth across all areas of the business, the doubling of the company’s share price year over year, and has positioned Lenovo for its fourth transformation during its 35 year history into a broader technology leader that combines devices + services + software + solutions.
“Our share price has doubled,” Yang said. “This not only shows our outstanding execution, but also that the market views Lenovo as a resilient, winning company. We were a strong team before the pandemic, and an even stronger team after.”
Recent performance highlights include:
- For the first three quarters of FY2020, revenue grew 12% and pre-tax profit increased 48% year over year.
- Lenovo remains the undisputed number one globally in PC and tablet market share, hitting historic highs.
- Mobile achieved double-digit revenue growth year-over-year in FYQ3.
- Revenue in the data center business grew by double digits year-over-year, significantly outperforming the market for four consecutive quarters.
- Services, software, and solutions grew almost 38% year-over-year in FYQ3, now accounting for ~8% of the company’s total revenue.
- Lenovo Capital Investment Group contributed financially and strategically through seven IPOs and reached record high investment gains.
Further, Lenovo plans an additional listing on the Shanghai stock exchange, broadening investor access and unlocking greater value. This growth happens in tandem with Lenovo’s strong commitment to sustainability, as seen through a 92 percent reduction in scope 1 and scope 2 greenhouse gas emissions. Lenovo also remains committed to environmentally sound transformation, with ambitious science-based targets and identifying what it will take to reach net-zero emissions by 2050.
Unveiling New Strategy for Next Decade
Lenovo’s strategy for the next decade of growth leverages all of the strong “building blocks” the company has today and combines them into end to end solutions that align to the tech market trends and solve customer business problems in three ways:
- Device Proliferation: Whether it’s “one PC, tablet, or other device per person” more people need dedicated devices. Lenovo will offer a full range of devices for each segment, develop new form factors, incorporate 5G connectivity, explore extended reality, and offer new collaboration tools.
- End to End Infrastructure: Today customers want integrated solutions combining hardware with software, support, and expertise. Lenovo will continue to expand its offering of a broad range of infrastructure portfolios, from on-premises datacenters to private and public clouds, and edge to cloud solutions.
- AI-Supported Intelligent Transformation: Lenovo offers the foundational technology for emerging trends, including IoT, big data, algorithms, and Edge computing. Lenovo will combine hardware with services to create intelligent solutions in smart manufacturing, smart education, smart retail, and smart cities.
Effective April 1, 2021 Lenovo aligned its business groups around a new organizational structure focused on Smart IoT, Smart Infrastructure and Smart Verticals:
- Intelligent Devices Group (IDG), focused on Smart IoT
- Infrastructure Solutions Group (ISG), focused on Smart Infrastructure
- Solutions & Services Group (SSG), focused on Smart Verticals & Services
Announcing Ambitious Goals for a New Fiscal Year
Speaking to employees around the world, company Chairman and CEO Yang outlined ambitious goals to accelerate the company’s transformation over the next fiscal year, including:
- Become #1 in PC market share across large enterprise, small to medium business, and consumers
- Achieve mobile profitability in expanded markets fueled by 5G innovations
- Grow twice as fast as the company across the new Solutions and Services Group
- Achieve double-digit growth in the Infrastructure Solutions Group
“We have an exciting future, but it takes solid steps to get there on our intelligent transformation journey,” Yang said. “Be proud but not complacent. Be optimistic but stay resilient. Aim high but stay grounded.”
About Lenovo
Lenovo (HKSE: 992) (PINK SHEETS: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy, and sustainable digital society. By designing, engineering, and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world. To find out more visit https://www.lenovo.com, follow us on LinkedIn, Facebook, Twitter, YouTube, Instagram, Weibo and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005568/en/
Contact information
Kristy Fair
krisfair@lenovo.com
919-257-6329
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
